Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Beaurang Pierre	2. Issuer Name and Ticker or Trading Symbol Nurix Therapeutics, Inc. [ NRIX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Business Officer
(Last) (First) (Middle) C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205	3. Date of Earliest Transaction (MM/DD/YYYY) 4/12/2021
(Street) SAN FRANCISCO, CA 94158 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/12/2021		M⁽¹⁾		2396	A	$0.84	6726	D
Common Stock	4/12/2021		M⁽¹⁾		5104	A	$1.11	11830	D
Common Stock	4/12/2021		S⁽¹⁾		4072	D	$26.8284 ⁽²⁾	7758	D
Common Stock	4/12/2021		S⁽¹⁾		2883	D	$27.669 ⁽³⁾	4875	D
Common Stock	4/12/2021		S⁽¹⁾		545	D	$28.6549 ⁽⁴⁾	4330	D
Common Stock								116666	I	By Trust ⁽⁵⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$0.84	4/12/2021		M ⁽¹⁾			2396	⁽⁶⁾	1/27/2026	Common Stock	2396	$0.00	0	D
Employee Stock Option (right to buy)	$1.11	4/12/2021		M ⁽¹⁾			5104	⁽⁶⁾	2/1/2027	Common Stock	5104	$0.00	36562	D

Explanation of Responses:
(1)	This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
(2)	Represents the weighted average sale price. The lowest price at which shares were sold was $26.25 and the highest price at which shares were sold was $27.24. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
(3)	Represents the weighted average sale price. The lowest price at which shares were sold was $27.27 and the highest price at which shares were sold was $28.18.
(4)	Represents the weighted average sale price. The lowest price at which shares were sold was $28.32 and the highest price at which shares were sold was $29.25.
(5)	The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
(6)	The option is fully vested.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Beaurang Pierre C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO, CA 94158			Chief Business Officer